The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: Anthracyclines, such as doxorubicin, though widely used in anticancer therapy, they are associated with cardiotoxic side-effects. The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier.
PATIENTS AND METHODS: Overall, 147 patients were randomized into the treatment arms. A total of 125 patients treated with doxorubicin without evidence of heart disease at the start of chemotherapy were analyzed. They were followed-up for up to 10 years after treatment start.
RESULTS AND CONCLUSION: A total of 47 patients completed the follow-up and 21 patients died, none due to cardiotoxicity events. Clinical signs of heart failure were not seen in any patients and no statistically significant differences between baseline and 10-year findings were seen for echocardiographic variables. No evidence of long-term cardiotoxicity was seen and nor metoprolol or enalapril offered an additional benefit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Anticancer research - 39(2019), 10 vom: 30. Okt., Seite 5703-5707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Georgakopoulos, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69PN84IO1A |
|---|
| Anmerkungen: |
Date Completed 07.10.2019 Date Revised 07.10.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.13769 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301779708 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301779708 | ||
| 003 | DE-627 | ||
| 005 | 20231225105332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.13769 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1005.xml |
| 035 | |a (DE-627)NLM301779708 | ||
| 035 | |a (NLM)31570470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Georgakopoulos, Peter |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2019 | ||
| 500 | |a Date Revised 07.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: Anthracyclines, such as doxorubicin, though widely used in anticancer therapy, they are associated with cardiotoxic side-effects. The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier | ||
| 520 | |a PATIENTS AND METHODS: Overall, 147 patients were randomized into the treatment arms. A total of 125 patients treated with doxorubicin without evidence of heart disease at the start of chemotherapy were analyzed. They were followed-up for up to 10 years after treatment start | ||
| 520 | |a RESULTS AND CONCLUSION: A total of 47 patients completed the follow-up and 21 patients died, none due to cardiotoxicity events. Clinical signs of heart failure were not seen in any patients and no statistically significant differences between baseline and 10-year findings were seen for echocardiographic variables. No evidence of long-term cardiotoxicity was seen and nor metoprolol or enalapril offered an additional benefit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Doxorubicin | |
| 650 | 4 | |a cardiotoxicity | |
| 650 | 4 | |a lymphoma | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Enalapril |2 NLM | |
| 650 | 7 | |a 69PN84IO1A |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Metoprolol |2 NLM | |
| 650 | 7 | |a GEB06NHM23 |2 NLM | |
| 700 | 1 | |a Kyriakidis, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Perpinia, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Karavidas, Apostolos |e verfasserin |4 aut | |
| 700 | 1 | |a Zimeras, Stelios |e verfasserin |4 aut | |
| 700 | 1 | |a Mamalis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Kouvela, Marousa |e verfasserin |4 aut | |
| 700 | 1 | |a Charpidou, Andriani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 39(2019), 10 vom: 30. Okt., Seite 5703-5707 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2019 |g number:10 |g day:30 |g month:10 |g pages:5703-5707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.13769 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2019 |e 10 |b 30 |c 10 |h 5703-5707 | ||